Amgen Competitors

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Volatility and Risk

Gilead Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Gilead Sciences and Amgen, as provided by MarketBeat.

Gilead Sciences presently has a consensus price target of $93.8276, indicating a potential upside of 48.16%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Gilead Sciences' higher probable upside, equities research analysts plainly believe Gilead Sciences is more favorable than Amgen.

Earnings & Valuation

This table compares Gilead Sciences and Amgen's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and Amgen's net margins, return on equity and return on assets.

Dividends

Gilead Sciences pays an annual dividend of $2.72 per share and has a dividend yield of 4.3%. Amgen pays an annual dividend of $6.40 per share and has a dividend yield of 2.6%. Gilead Sciences pays out 44.3% of its earnings in the form of a dividend. Amgen pays out 43.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 1 consecutive years.

Insider and Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Amgen beats Gilead Sciences on 13 of the 17 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Vertex Pharmaceuticals and Amgen, as provided by MarketBeat.

Vertex Pharmaceuticals presently has a consensus price target of $289.6552, indicating a potential upside of 28.42%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than Amgen.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Amgen on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for Regeneron Pharmaceuticals and Amgen, as provided by MarketBeat.

Regeneron Pharmaceuticals presently has a consensus price target of $618.3929, indicating a potential upside of 19.40%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Summary

Regeneron Pharmaceuticals beats Amgen on 9 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Institutional and Insider Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 0.5% of Biogen shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Biogen and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biogen and Amgen's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Biogen and Amgen, as reported by MarketBeat.

Biogen currently has a consensus price target of $306.1290, indicating a potential upside of 10.98%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Amgen.

Summary

Amgen beats Biogen on 8 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Alexion Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Alexion Pharmaceuticals and Amgen, as reported by MarketBeat.

Alexion Pharmaceuticals currently has a consensus price target of $152.9615, indicating a potential downside of 2.39%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Amgen's stronger consensus rating and higher probable upside, analysts clearly believe Amgen is more favorable than Alexion Pharmaceuticals.

Summary

Amgen beats Alexion Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Institutional and Insider Ownership

87.2% of Seagen shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 31.1% of Seagen shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Seagen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Seagen and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Seagen and Amgen's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Seagen and Amgen, as reported by MarketBeat.

Seagen currently has a consensus price target of $185.5714, indicating a potential downside of 0.10%. Amgen has a consensus price target of $255.52, indicating a potential upside of 4.09%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than Seagen.

Summary

Seagen beats Amgen on 8 of the 15 factors compared between the two stocks.